Raajit K. Rampal, MD, PhD

Articles

Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs

July 6th 2022

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs

June 4th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

October 12th 2021

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

September 2nd 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

August 3rd 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

July 22nd 2021

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.

Dr. Rampal on the Evolution of Prognostic Models in Essential Thrombocythemia

December 8th 2020

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Dr. Rampal on Tools to Estimate Prognosis in Myelofibrosis

October 13th 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Dr. Rampal on the Evolving Understanding of Genomic Alterations in MPNs

September 24th 2020

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

Dr. Rampal on Investigational Agents in MPNs

February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

January 24th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

January 15th 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Dr. Rampal on Treatment Options in Polycythemia Vera

January 8th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.